Quanterix FY Conference Summary Company Overview - **Company**: Quanterix (NasdaqGM: QTRX) - **Industry**: Life Sciences Tools and Diagnostics - **Key Management**: Everett Cunningham (CEO), Vandana Sriram (CFO) Core Points and Arguments Leadership Transition - Everett Cunningham, with over 30 years in healthcare, joined Quanterix from Illumina, attracted by the need for breakthrough technologies in neurology, oncology, and immunology [6][7] - Emphasized the solid base business in research tools and the potential for growth in diagnostics, particularly in Alzheimer's [7][8] Financial Health - Quanterix has a strong balance sheet with $100 million in cash and no debt [8] - The company aims to achieve breakeven cash flow in the second half of the year and has set a synergy target of $84 million from the Akoya acquisition by the end of Q1 [8] Growth Strategy - Projected growth for 2026 is between 0%-3%, with a focus on prioritizing next-generation platforms and technologies [14][16] - Plans to build a comprehensive diagnostics strategy, including reimbursement strategies and clinical utility studies, with results expected mid-year [18][19] Performance Insights - The fourth quarter showed a significant improvement, with consumables driving growth and a recurring revenue profile now at 75% [21][22] - The company is seeing a reduction in cash burn, down to approximately $3 million from previous levels of $15 million-$20 million [22] Akoya Acquisition - The acquisition has diversified Quanterix's business from 90% neurology to 60% neurology and 40% oncology/immunology, enhancing the company's market position [23][24] - Early integration efforts have been positive, with a unified company culture emerging [25][26] Market Position and Future Outlook - The company anticipates a return to high single-digit growth rates in a normalized market, driven by consumables and diagnostic partnerships [29][36] - The focus will be on optimizing technology and expanding the Accelerator Laboratory's role in generating insights for next-gen assay development [46][47] Alzheimer's Diagnostics - Quanterix is working on a multi-analyte blood test for Alzheimer's, with a 510(k) submission made in January and results expected in 6-9 months [66][73] - The company aims to establish an end-to-end strategy for diagnostics, leveraging its CLIA lab capabilities [95][96] Competitive Landscape - Quanterix's LucentAD test is positioned as a unique offering with high sensitivity and specificity, differentiating it from competitors [103][104] - The company welcomes competition as it indicates market attractiveness and is committed to maintaining a strong commercial approach [121][123] Additional Important Insights - The Accelerator Laboratory serves as a leading indicator for customer interests and next-gen assay development [46][47] - The company is expanding its infrastructure outside the U.S., particularly in markets with aging populations like China and Korea [116] - Future growth opportunities are anticipated from service offerings similar to those in the Accelerator Laboratory [65] This summary encapsulates the key points discussed during the Quanterix FY Conference, highlighting the company's strategic direction, financial health, and market positioning within the life sciences tools and diagnostics industry.

Doctors and nurses need fast insights without extra complexity. Gaston Sandoval explains how AI PCs can unlock new intelligence on-device for diagnostics and frontline workflows. Discover more: https://www.amd.com/en/products/processors/business-systems.html Follow us on AMD Enterprise LinkedIn: https://www.linkedin.com/showcase/amd-enterprise/ Follow us on AMD Channel Partner LinkedIn: https://www.linkedin.com/showcase/amd-channel-partners/ *** Subscribe: https://bit.ly/Subscribe_to_AMD Join the AMD Gaming ...

Financial Data and Key Metrics Changes - For the full year 2025, sales were $24.6 billion, with core revenue increasing by 2% and adjusted diluted net earnings per common share rising by 4.5% to $7.80 [7][8] - The adjusted operating profit margin was 28.2%, and free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [7][8] - In Q4 2025, sales reached $6.8 billion, with core revenue growth of 2.5% [11] Business Line Data and Key Metrics Changes - Core revenue in the biotechnology segment increased by 6%, while discovery and medical declined at a high single-digit rate due to prior year comparisons and funding constraints [13][14] - Bioprocessing core revenue grew high single digits, driven by strong demand for monoclonal antibodies [14][15] - In diagnostics, core revenue increased by 2%, with clinical diagnostics growing mid-single digits [18] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [12] - High growth markets saw mid-single digit increases, with solid growth outside of China, which experienced a low single-digit decline [12] Company Strategy and Development Direction - The company expects gradual end market improvements to continue, supported by a differentiated portfolio and the Danaher Business System [7][23] - Focus on innovation and new product introductions, with approximately 25% year-over-year growth in new product revenue [11][8] - Anticipation of core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the bioprocessing market, driven by robust FDA approvals and increasing demand for biologics [16][23] - The company remains cautious about the academic and government demand, which has been muted but stable [6][17] - Management highlighted the importance of a recovering biotech funding environment for the life sciences business [91][92] Other Important Information - The company has maintained a strong free cash flow generation for 34 consecutive years, exceeding a 100% conversion ratio [8] - The company is well-positioned for M&A opportunities, with a constructive environment and strong cash flow generation [64][66] Q&A Session Summary Question: Guidance for core revenue growth - Management confirmed a core revenue growth guidance of 3%-6% for 2026, with bioprocessing expected to remain strong at high single digits [27][28] Question: Bioprocessing order book and growth - The order book supports high single-digit growth for bioprocessing, with equipment orders showing sequential growth [33][34] Question: Strength in SCIEX and end market recovery - SCIEX experienced mid-single-digit growth, driven by innovation and improvement in the pharma end market [40][41] Question: Margin expectations for 2026 - Management expects margins to follow core growth, with benefits from cost actions expected to materialize in the second half of the year [42][43] Question: Biotech funding impact on life sciences - The biotech segment is sensitive to funding improvements, which could enhance order volumes [91][92] Question: Reshoring trends in bioprocessing - Management noted ongoing discussions about reshoring, indicating a potential long-term investment cycle in bioprocessing [94][95]

Core Insights - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the 12 best genomics stocks to invest in [1] Price Adjustments - Canaccord lowered its price objective for Tempus AI, Inc. from $95 to $80 while maintaining a buy rating [2] - BofA also reduced its price estimate for Tempus AI, Inc. from $90 to $80, reaffirming a neutral recommendation [3] Market Outlook - Canaccord noted that the sector momentum from the latter half of 2025 is expected to continue into 2026, particularly in life science instruments and diagnostics [2] - BofA anticipates a rebound in biopharma spending, which is expected to provide significant support for the industry [4] Company Overview - Tempus AI, Inc. is a healthcare technology company that offers molecular genotyping, polymerase chain reaction profiling, next-generation sequencing diagnostics, and various pathology tests to medical professionals and other stakeholders [5]

Core Insights - The company reported its third-quarter results, which aligned with expectations, indicating stability in performance [1] Business Performance - Life Sciences segment remained flat, while Diagnostics experienced a slight increase [1] - Organic growth (OG) was up by 1%, and there was an improvement in margins [1] - Earnings per share (EPS) exceeded expectations due to favorable below-the-line items [1] Market Activity - Increased activity was noted in the Life Sciences sector, particularly in instrumentation, which performed better than anticipated despite still being down [1]

I'm 8 years old, sitting on the edge of an exam table, extremely anxious. You don't have cancer, the doctor tells me. You're too young.But do you know that. I ask. She runs a basic blood test.It's normal. See, you're fine. But where does it say I don't have cancer, though.I ask. She sigh, "This is just the best that we can do." Six months earlier, my grandmother, Caroline, the person everybody said I was just alike, had been diagnosed with stage 4 ovarian cancer. And a few months later, she was gone.At 8, a ...

Financial Data and Key Metrics Changes - The company reported sales of $6.1 billion in Q3 2025, achieving a 3% core revenue growth year-over-year [8][10] - Gross profit margin for Q3 was 58.2%, with an adjusted operating profit margin of 27.9%, up 40 basis points year-over-year [9][10] - Adjusted diluted net earnings per share were $1.89, reflecting a 10% increase year-over-year [10] Business Line Data and Key Metrics Changes - Core revenue in the biotechnology segment increased by 6.5%, while core revenue in discovery and medical grew low single digits [14][18] - Bioprocessing core revenue grew high single digits, driven by double-digit growth in consumables, although equipment revenue declined in the high teens year-over-year [15][16] - Core revenue in diagnostics increased by 3.5%, with clinical diagnostics up low single digits and Cepheid's core revenue up mid single digits [19][20] Market Data and Key Metrics Changes - Core revenues in developed markets were up mid single digits, while high growth markets saw low single-digit growth, impacted by a mid single-digit decline in China [8][9] - The company noted a modest recovery in pharma R&D spending, although it remains below historical levels [7][18] Company Strategy and Development Direction - The company is focused on leveraging the Danaher Business System to drive productivity gains and mitigate geopolitical pressures [8][24] - Continued investment in innovation, particularly in digital and artificial intelligence initiatives, is a priority to strengthen long-term competitive positioning [8][10] - The long-term outlook for the biologics market remains healthy, driven by increasing global production of biological medicines, particularly monoclonal antibodies [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong Q3 results and the ability to exceed revenue, earnings, and cash flow expectations [7][10] - The company expects core revenue growth in the low single-digit percentage range for Q4 2025 and maintains its full-year adjusted diluted EPS guidance of $7.70 to $7.80 [21][22] - For 2026, the company anticipates core revenue growth in the 3% to 6% range, assuming modest recovery across end markets [22][23] Other Important Information - The company generated $1.4 billion in free cash flow in Q3 and $3.5 billion year-to-date, resulting in a free cash flow to net income conversion ratio of 146% [10][24] - A new share repurchase program was approved, authorizing the purchase of up to 35 million additional shares of common stock [10][24] Q&A Session Summary Question: What are the expectations for fiscal year 2026? - Management indicated a range of 3% to 6% top-line growth for 2026, with a focus on modest recovery in end markets [27][30] Question: What factors could influence the 3% versus 6% growth? - The company noted that improvements in the market and policy environment would be key to achieving higher growth [28][30] Question: How is the company addressing the challenges in the diagnostics segment, particularly in China? - Management acknowledged a conservative view on diagnostics in China, expecting a manageable headwind of $75 million to $100 million [36][37] Question: What is the outlook for the biotechnology equipment market? - There is cautious optimism for equipment investments, with management noting increased confidence among pharma customers regarding capital investments [45][46] Question: How does the company view capital deployment between M&A and share repurchases? - The company maintains a strong bias towards M&A but is also open to share repurchases when valuations are attractive [81][82]

Financial Data and Key Metrics Changes - Sales for the third quarter were $6.1 billion, with a 3% core revenue growth year-over-year [7] - Gross profit margin was 58.2%, and adjusted operating profit margin increased by 40 basis points to 27.9% year-over-year [8] - Adjusted diluted net earnings per share were $1.89, reflecting a 10% increase year-over-year [8] - Free cash flow generated in the quarter was $1.4 billion, with a year-to-date free cash flow to net income conversion ratio of 146% [9] Business Line Data and Key Metrics Changes - Core revenue in the biotechnology segment increased by 6.5% [12] - Core revenue in bioprocessing grew high single digits, driven by strong demand for consumables, while equipment revenue declined in the high teens year-over-year [13] - Core revenue in life sciences decreased by 1%, with consumables facing declines due to lower demand from major customers [16] - Core revenue in diagnostics increased by 3.5%, with significant growth in clinical diagnostics outside of China [18] Market Data and Key Metrics Changes - Core revenues in developed markets were up mid-single digits, while high growth markets saw low single-digit growth, primarily affected by a decline in China [7][8] - The biotechnology and life sciences businesses in China experienced declines due to volume-based procurement and reimbursement policy changes [8] Company Strategy and Development Direction - The company is focused on leveraging the Danaher Business System to drive productivity gains and mitigate geopolitical pressures [6] - Continued investment in innovation, particularly in digital and artificial intelligence initiatives, is a priority to strengthen long-term competitive positioning [6] - The long-term outlook for the biologics market remains healthy, with expectations of strong demand growth for monoclonal antibodies [15] Management's Comments on Operating Environment and Future Outlook - Management noted a modest recovery in pharma R&D spending, although it remains below historical levels [5] - The company expects cautious equipment spending through the remainder of the year due to uncertainties in the policy environment [14] - For 2026, the company anticipates core revenue growth in the range of 3% to 6%, assuming modest recovery across end markets [20][21] Other Important Information - The company deployed approximately $2 billion for share repurchases and announced a new program to buy up to 35 million additional shares [9] - Several new product launches were highlighted, including advancements in bioprocessing and diagnostics [10][12] Q&A Session Summary Question: What are the expectations for fiscal year 2026? - Management indicated a range of 3% to 6% core revenue growth, with a focus on modest recovery in end markets [28][34] Question: What factors could influence the 3% versus 6% growth? - The company highlighted the need for improved market conditions and clarity in investment decisions from customers [34][35] Question: How is the company addressing the challenges in the diagnostics segment, particularly in China? - Management acknowledged a conservative view on the diagnostics business in China, expecting manageable headwinds [43][44] Question: What is the outlook for the biotechnology segment? - The company expects high single-digit growth in bioprocessing, driven by strong demand for monoclonal antibodies [48][49] Question: How does the company view capital deployment between M&A and share repurchases? - There is a strong bias towards M&A, but the company remains open to share buybacks at current levels [94]

Financial Data and Key Metrics Changes - Sales for the third quarter were $6.1 billion, with a core revenue growth of 3% year over year [9] - Adjusted diluted net earnings per share were $1.89, reflecting a 10% increase year over year [10] - Free cash flow generated in the quarter was $1.4 billion, with a year-to-date free cash flow to net income conversion ratio of 146% [10] Business Line Data and Key Metrics Changes - Core revenue in the biotechnology segment increased by 6.5%, while core revenue in life sciences decreased by 1% [14][18] - Core revenue in diagnostics increased by 3.5%, with clinical diagnostics showing low single-digit growth outside of China [20] - Bioprocessing core revenue grew in high single digits, driven by strong demand for consumables [15] Market Data and Key Metrics Changes - Core revenues in developed markets were up mid-single digits, while high growth markets saw low single-digit growth, with a mid-single-digit decline in China [9] - Demand from academic and government customers remained soft but stable, impacting life sciences consumables [19] Company Strategy and Development Direction - The company is focused on leveraging the Danaher Business System to drive productivity gains and invest in innovation, particularly in digital and AI initiatives [7][25] - The long-term outlook for the biologics market remains strong, driven by increasing global production of biological medicines [17] - The company is maintaining a strong bias towards M&A while also considering share repurchases as a capital allocation strategy [93] Management's Comments on Operating Environment and Future Outlook - Management noted a modest recovery in pharma R&D spending, although it remains below historical levels [6] - For 2026, the company expects core revenue growth in the range of 3% to 6%, assuming modest recovery across end markets [23] - The company anticipates respiratory revenue at Cepheid to be approximately $1.7 billion in 2026, consistent with expectations for 2025 [24] Other Important Information - The company deployed approximately $2 billion towards share repurchases in the quarter and has authorized an additional buyback program for up to 35 million shares [10] - New product launches in biotechnology and diagnostics are expected to enhance competitive positioning and support customer needs [11][13] Q&A Session Summary Question: Insights on fiscal year 2026 guidance - Management provided context on the 3% to 6% growth range, indicating that a modest recovery in end markets is expected, with bioprocessing growth trends remaining strong [31][35] Question: Concerns regarding China diagnostics and VBP - Management indicated that they are managing headwinds from VBP and expect a modest impact of $75 to $100 million for the next year [44] Question: Equipment recovery in biotechnology - Management noted that while there is increased activity and discussions with pharma customers, actual orders have not yet materialized, leading to a cautious outlook for equipment spending [55] Question: Clarification on diagnostics growth expectations - Management expects mid-single-digit growth for Beckman outside of China and anticipates continued growth in Cepheid's non-respiratory business [57][58] Question: Impact of recent policy changes on capital investment - Management observed increased confidence among pharma executives regarding capital investments due to stabilizing tariffs and workable solutions for policy discussions [76]

Healthcare AI Potential - AI can improve disease prevention and diagnostics, exemplified by early breast cancer detection leading to a nearly 99% survival rate, contrasting with a 33% rate upon lymph node spread [6][7] - AI models can analyze chest X-rays to diagnose diabetes, assess biological aging, and predict 10-year heart attack or stroke risk [8] - Retinal images can predict kidney, gallbladder, or liver disease, while brain MRIs can detect early Alzheimer's and indicators of psychiatric conditions [9][10] AI Scaling Human Capabilities - AI-driven large language models (LLMs) accelerate drug discovery by predicting protein shapes with high accuracy, reducing research time from years to months [14][15] - Digital twins, aggregating data from various sources, enable testing experimental drugs on a virtual patient before actual administration, and predicting ICU complications [16][17][18] - AI can create digital twin models for organ transplantation, matching donor organs and recipients to minimize post-transplant rejections [19] Improving Healthcare Experience - Personalized AI agents can automate healthcare tasks, such as scheduling appointments, verifying insurance, arranging transportation, and managing medication delivery [21][22][23][24][25] - AI's personalization of healthcare technology aims to be intuitive, anticipatory, and teachable, enhancing the overall patient experience [26] Considerations and Future - Despite AI's benefits, the healthcare industry acknowledges the irreplaceable human element in healthcare, emphasizing the need for thoughtful AI development and execution [28][29][30] - AI and technology in healthcare are expected to usher in an era of abundance, empowering individuals to take control of their medical journeys [31]